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http://dx.doi.org/10.1016/j.jmii.2013Trichosporon asahii is a rare opportunistic infection, especially in children, causing a life-
threatening fungal infection underlying hematologic malignancies. Predisposing factors for
infection with this pathogen are immunodeficiency including underlying malignancy, organ trans-
plantation, extensive burns, human immunodeficiency virus infection, corticosteroid therapy,
prosthetic valve surgery, and peritoneal dialysis. In the literature, a breakthrough under caspofun-
gin, micafungin therapy is reported. In this article we report on a 16-year-old patient with Ewing
sarcoma who had T. asahii sepsis. The patient died although he had been receiving caspofungin
for less than3monthsandamphotericinB therapy for3days. Apostmortemstudyofconchal tissues
revealed T. asahii and mucormycosis histopathologically, and blood culture grew T. asahii.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Trichosporon asahii is a rare opportunistic yeast-like fungus
causing rare infections in children. Despite antifungalt of Pediatric Infectious Dis-
e University, Sihhiye 06100,
ail.com (E. Karadag-Oncel).
an Society of Microbiology. Publis
commons.org/licenses/by-nc-nd/
.01.003therapy with amphotericin B, the mortality rate is high
(80%) and early initiation of treatment may increase sur-
vival of these patients.1 Herein, we report on a previously
treated patient with Ewing sarcoma who died because of
T. asahii sepsis. Three days of liposomal amphotericin B
therapy following 3 months of caspofungin therapy did not
help to achieve a favorable outcome.hed by Elsevier Taiwan LLC. This is an open access article under the
4.0/).
Figure 1. Necrotic lesion in the nasal area.
Figure 2. Fungal elements including several true hyphae and
blastoconidia in samples of conchal lesion.
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A 16-year-old boy previously had been treated for Ewing
sarcoma in the region of the right superior pubic ramus. He
had received intensive chemotherapy and underwent
hemipelvectomy after radiotherapy. A lesion with recurrent
pus discharge on the area of radiotherapy (right inguinal
area) had worsened, with urine leakage from the lesion
despite antibiotic therapy. The patient underwent a second
operation for implant insertion to the right pelvic area in
August 2008, and had been hospitalized seven times
between September 2008 and January 2011 for pus dis-
charge at the right inguinal area after receiving appropriate
antibiotic therapy. He and his family had been advised
that surgery was necessary for removal of the implant, but
they did not provide consent for this process. He eventually
was hospitalized to undergo implant removal in June 2011.
Surgery included implant excision and bypass between the
saphenous vein, iliac artery, and femoral artery. Because of
massive arterial bleeding postoperatively, the patient
underwent a second operation for right hip dislocation, total
right lower extremity amputation, and urinary bladder
reconstruction. Becausehecouldnotbeextubatedandwas in
septic shock with hypotension, anuria, and worsening kidney
function tests, antibiotic therapy was planned with mer-
openem, ciprofloxacin, colistin, and linezolid because of the
extended spectrumbeta-lactamase activity ofAcinetobacter
baumannii (colistin sensitive) and Escherichia coli (mer-
openem, imipenem, ciprofloxacin, and amikacin sensitive).
The patient’s hypotension did not respond to dopamine
and dobutamine therapy, a chest X-ray revealed pleural
effusion, thoracentesis revealed fluid with characteristics
of transudate, and a black-colored necrotic edematous
lesion was present in the nasal area (Fig. 1).
Although the patient did not have a positive blood culture,
ongoing local infection was present. Therefore, antimicrobial
therapy including meropenem, colistin, teicoplanin, and cas-
pofungin was reorganized to include meropenem, colistin,
teicoplanin, and liposomal amphotericin B. Paranasal CT
yielded increased density in the right maxillary sinus com-
patible with infection or hemorrhage, with increased sub-
cutaneous nodular density suggesting infection in the left
middle meatus. In the following hours the patient had cuta-
neous necrosis in the dorsal area necrosis in the nasal bone.
The patient’s disease progress was so rapid that mortality
couldnotbeprevented, 3daysafter theskinfindingsoccurred.
Blood culture yielded T. asahii after minimum inhibitory con-
centration values were exceeded for that isolate at 4 mg/mL
for fluconazole and 0.03 mg/mL for voriconazole. Postmortem
study of tissues from the nose and conchae revealed wide-
spread necrosis, karyorrhexis, and mixed inflammatory infil-
trate along with septated fungal hyphae and spores (Fig. 2).
Additionally, a group of nonseptated mucormycotic hyphae
was also detected. However T. asahii was the only infectious
agent isolated from the cultures of necropsy samples.
Discussion
The non-Candida yeast-Trichosporon species is an increas-
ingly common pathogen in immunocompromised hosts.
These species have been isolated from various types ofclinical specimens, including blood, skin biopsy, and urine
specimens,2e4 and reported as colonization of the gastro-
intestinal tract, skin, mucosal surfaces and in addition to
stool, central venous catheter, sputum, and hair.2 T. asahii
is the most frequent species involved in disseminated
infections.5,6 Cutaneous involvement with papulonodular or
pustular lesions, especially necrotic appearance, has been
148 A. Ozkaya-Parlakay et al.frequently observed and could be indicative of tricho-
sporonosis. Biopsies of these skin lesions have revealed
Trichosporon species in more than 75% of the cases, and are
helpful to promptly confirm the etiology and initiate
appropriate treatment.6 Papulonodular or pustular skin
findings, which are frequently seen and described in the
literature, were absent in our patient.
Early diagnosis of trichosporonosis remains a challenge,
and the Trichosporon species are less susceptible to some
empirical or prophylactic antifungal drugs such as caspo-
fungin and amphotericin B.7 Amphotericin B has been
shown to have a limited in vitro effect against Trichosporon
species.5 Susceptibilities to antifungal agents are variable
in the literature; in vitro activity does not always correlate
with efficacy in vivo. Recently, new azoles have appeared
as promising therapies for this infection. In vitro studies
have shown that azoles, particularly voriconazole, were
more potent than amphotericin B.8 In a recent study vor-
iconazole and itraconazole were found to be the most
active drugs in vitro against all the Trichosporon species
tested, whereas caspofungin and amphotericin B demon-
strated poor activity.9 In patients who cannot be treated
with voriconazole because of its adverse effects, ampho-
tericin B, flucytosine, fluconazole, and itraconazole might
be alternative antifungal agents,10 although multidrug
resistance to these agents leading to treatment failure has
been reported.2 It is reported that echinocandins have low
activity against Trichosporon species and are not recom-
mended for the treatment of trichosporonosis.11,12 To the
best of our knowledge, 14 patients have been reported in
the literature with invasive trichosporonosis during the use
of echinocandins.13 Therefore, the risk of Trichosporon
infection should not be overlooked in patients with risk
factors and those receiving echinocandins empirically or
prophylactically as did our patient.
Mucormycosis is a rare but highly invasive infection,
which may manifest in different anatomic locations such as
in paranasal sinuses, the rhinoorbital and rhinoorbitocere-
bral regions, pulmonary system, gastrointestinal tract, and
cutaneous sites, and rarely, in disseminated form. The dis-
ease has a high mortality rate; however, better prognosis
can be achieved with cutaneous infections, and mucormy-
cosis was rarely seen in a disseminated form.14 In a report of
12 pediatric cases overall mortality was reported at 67%.15
Although mucormycosis was diagnosed in histologic nasal
specimens, T. asahii was cultured from the nasal region,
hemodialysis catheter, and periferically but mortality could
still be associated with coinfection of T. asahii together with
mucormycosis in our patient. The first case report of the
coinfection with mucormycosis and Trichosporon in the lit-
erature was published in 200616; posaconazole together with
a high dose of amphotericin B, aggressive surgical debride-
ment and hyperbaric oxygen therapy resulted in cure of a
disseminated fungal necrotizing fasciitis.
In the literature, breakthrough trichosporonosis has
been reported during the administration of various anti-
fungal agents, including amphotericin B, caspofungin,
micafungin, and azoles.5,14,15 Unfortunately, our patient
experienced rapid deterioration although he was treated
with caspofungin and Trichosporon could only be cultured
and shown in postmortem studies. Factors that
enhance mucosal colonization and subsequent invasion ofTrichosporon species include broad-spectrum antibiotic
treatment and breaks in mucosal barriers.3,11 Because our
patient had renal function impairment, antifungal therapy
was initiated with caspofungin. It is highly likely that
combination therapy with drugs acting synergistically on
different sites such as caspofungin and amphotericin B for
trichosporonosis, as aspergillosis, may have better out-
comes than fungicidal activity of antifungal agents when
used alone.7e9 Unfortunately, the antifungal treatment
in our case did not yield a successful outcome. However,
therapy with liposomal amphotericin B was found to
be effective in eradicating T. asahii from blood, and was
also well tolerated and associated with resolution of fever
in our patient. The mortality of our patient makes it
clear that it is vital to keep in mind the possibility of
trichosporonosis even under antifungal therapy especially
echinocandins. In addition, early diagnosis together with
initiation of rapid and appropriate therapy could be a life-
saving process and assist in achieving a favorable outcome.
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